G-CSF支持下的强化巩固治疗:≥60岁急性髓系白血病患者的耐受性、安全性、住院时间缩短及疗效
本研究评估氟达拉滨联合阿糖胞苷第1周期、中剂量阿糖胞苷第2至4周期强化巩固方案在老年急性髓系白血病患者中的疗效与可行性,并分析培非格司亭对中性粒细胞减少持续时间、总体毒性及住院时间的影响。39例中位年龄69.9岁、诱导化疗后达完全缓解的患者中,23/39例完成全部4个周期;第2、4周期常规给予培非格司亭较第3周期按需给予时中性粒细胞减少持续时间缩短,中位总生存1.1年,<75岁与≥75岁患者间差异显著。
要点
- ≥60岁急性髓系白血病患者可接受强化巩固治疗,<75岁患者可能获益。
- 巩固治疗期间常规给予培非格司亭可缩短中性粒细胞减少时间和住院时间。
- 39例中23例(59.0%)完成全部4个巩固周期,中位总生存1.1年,5年生存概率32%。
核心结论
- 强化巩固治疗可用于≥60岁急性髓系白血病患者,<75岁患者可能从中获益。
- 巩固治疗期间常规给予培非格司亭可缩短中性粒细胞减少时间和住院时间。
研究设计与样本
- 研究纳入39例诱导化疗后达完全缓解的初治老年急性髓系白血病患者,中位年龄69.9岁。
- 第1周期采用氟达拉滨联合阿糖胞苷,第2至4周期采用中剂量阿糖胞苷(IDAC)。
- 比较第2、4周期(从第6天起常规给予培非格司亭,IDAC-P)与第3周期(仅严重感染和/或中性粒细胞减少延长时给予培非格司亭,IDAC)对中性粒细胞减少和住院的影响。
主要发现
- 23/39例(59.0%)完成全部4个计划周期,5/39例(12.8%)完成3个周期,3/39例(7.7%)完成2个周期,8/39例(20.5%)完成1个巩固周期。
- 严重中性粒细胞减少的中位持续时间:第2周期(IDAC-P)7天,第3周期(IDAC)11.5天,第4周期(IDAC-P)7.5天(P < .05)。
- 中位总生存为1.1年,<75岁与≥75岁患者间差异显著(P < .05)。
- 5年生存概率为32%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The aim of this study was to evaluate the efficacy and feasibility of intensified consolidation therapy employing fludarabine and ARA-C in cycle 1 and intermediate-dose ARA-C (IDAC) in cycles 2 through 4, in elderly acute myeloid leukemia (AML) patients and to analyze the effects of pegfilgrastim on the duration of neutropenia, overall toxicity, and hospitalization-time during consolidation in these patients. Thirty nine elderly patients with de novo AML (median age 69.9 years) who achieved complete remission (CR) after induction-chemotherapy were analyzed. To examine the effect of pegfilgrastim on neutropenia and hospitalization, we compared cycles 2 and 4 where pegfilgrastim was given routinely from day 6 (IDAC-P) with cycle 3 where pegfilgrastim was only administered in case of severe infections and/or prolonged neutropenia. All four planned cycles were administered in 23/39 patients (59.0%); 5/39 patients (12.8%) received 3 cycles, 3/39 (7.7%) 2 cycles, and 8/39 (20.5%) one consolidation-cycle. The median duration of severe neutropenia was 7 days in cycle 2 (IDAC-P), 11.5 days in cycle 3 (IDAC), and 7.5 days in cycle 4 (IDAC-P) (P < .05). Median overall survival was 1.1 years and differed significantly between patients aged <75 and ≥75 years (P < .05). The probability to be alive after 5 years was 32%. Together, intensified consolidation can be administered in AML patients ≥60, and those who are <75 may benefit from this therapy. Routine administration of pegfilgrastim during consolidation shortens the time of neutropenia and hospitalization in these patients.
引用
- Sperr WR, Herndlhofer S, Gleixner K, et al. Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years. Am J Hematol. 2017. PMID: 28699225. doi:10.1002/ajh.24847
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。